We use essential cookies (authentication, your saved goals/stack) by default. With your permission we’ll also enable privacy-respecting analytics (Vercel Web Analytics, anonymous load-time metrics) and error-replay diagnostics (Sentry — DOM snapshots only when an error fires) so we can fix bugs faster. Learn more about cookies
Thi6.5
Thiamidol Research
Mostly mechanism / observational
9 peer-reviewed studies
What the evidence says
Mostly mechanism / observational
Most Thiamidol studies are mechanism or observational rather than RCTs that measure a clinical effect — keep findings provisional.
Most evidence is from high-quality randomised trials published 2018–2024 with a typical study size of 48 participants.
Based on 9 studies · 5 RCTs · 2,128 total participants
Confidence
High confidence
By outcome
Skin tone & pigmentationmMASI reduction around 43% over 90 days in facial melasma, comparable to 4% hydroquinone; effect fades after stopping · 4-12 weeks
Mostly mechanism / observational8 studies
Muscle strength & power
Too few graded studies2 studies
Safety profile
Too few graded studies1 study
Active research area
7 studies in the last 5 years
20182024
1In VitroCited 159×2018
In plain English: Screening 50,000 compounds against recombinant HUMAN tyrosinase, thiamidol had an IC50 of 1.1 µmol/L, while hydroquinone and arbutin inhibited human tyrosinase only weakly, in the millimolar range.
Mann T, et al. · J Invest Dermatol (2018)
The discovery paper, and the reason this ingredient exists: most tyrosinase inhibitors were screened against MUSHROOM tyrosinase, which is why so many lack clinical effect.
Thiamidol inhibits human tyrosinase at IC50 1.1 µmol/L but mushroom tyrosinase only at 108 µmol/L — a hundredfold the other way round. The two enzymes need different molecules.
Hydroquinone and arbutin were weak on the human enzyme (millimolar IC50); kojic acid was weak too (IC50 > 500 µmol/L).
2RCTCited 40×n=50 · small study2021
In plain English: Over 90 days in 50 women with facial melasma, mMASI fell 43% (95% CI 35-50) with 0.2% thiamidol and 33% (95% CI 23-42) with 4% hydroquinone, with NO significant difference between the groups.
The comparison that matters: head to head against 4% hydroquinone, the prescription-strength benchmark.
⚠️ NOT a superiority result, and not a formal non-inferiority design either: mMASI fell 43% vs 33% and the paper states the improvement "did not differ" from 4% hydroquinone.
Evaluator-blinded, 50 women, 90 days; 86% were Fitzpatrick phototypes III-IV.
3Systematic ReviewCited 14×n=1,853 · large study2022
In plain English: Across 47 studies and 1,853 subjects graded with a modified GRADE scale, thiamidol was among the agents with high-quality studies — while retinoids, hydroxy acids and broad-spectrum sunscreen were supported by the greatest number of them.
Chaowattanapanit S, et al. · J Dermatolog Treat (2022)
Independent context, not a thiamidol paper: 47 of 1,224 screened studies, 1,853 subjects, GRADE-assessed.
Thiamidol is listed among agents WITH high-quality studies, alongside retinoids, hydroxy acids, corticosteroids, niacinamide and plant-derived products.
⚠️ But retinoids, hydroxy acids and broad-spectrum sunscreen are the ones "supported by the greatest number of high-quality studies". Thiamidol is in the room, not leading it.
4RCTCited 20×n=48 · small study2021
In plain English: MASI improved significantly versus vehicle across 24 weeks, but at follow-up 13-20 weeks after treatment stopped, MASI was similar for thiamidol and vehicle.
Philipp-Dormston WG, et al. · J Dermatol (2021)
The study the abstract calls the FIRST 24-week randomized, double-blind, vehicle-controlled assessment of thiamidol in moderate-to-severe melasma, with a subsequent regression phase.
⚠️ The benefit did not persist. At follow-up 13-20 weeks after stopping, MASI was still below baseline but SIMILAR between thiamidol and vehicle.
⚠️ Skin lightness and quality of life improved versus baseline but showed NO significant difference between thiamidol and vehicle.
5RCTCited 9×n=40 · small study2023
In plain English: Replacing hydroquinone with isobutylamido-thiazolyl-resorcinol in a triple combination gave an mMASI change of -4.33 against -2.84 for Kligman’s trio, a mean difference of -1.49 (95% CI -3.52 to 0.54, p = 0.14).
Tests the ingredient inside the gold-standard regimen: ITR plus retinoic acid plus corticosteroid, against Kligman’s trio.
⚠️ NOT superior. The between-group difference was -1.49 with a 95% CI spanning zero (-3.52 to 0.54) and p = 0.14.
Quality of life did separate: MelasQoL -12.57 (p = 0.0006) for the new trio versus -6.66 (p = 0.0515) for Kligman’s.
6Systematic ReviewCited 3×2024
In plain English: Across 14 clinical studies all reporting statistically significant improvement, the authors conclude that topical ITR can significantly reduce hyperpigmentation, however the evidence for its use is limited and further investigation is warranted.
Ashraf S, et al. · J Drugs Dermatol (2024)
The dedicated systematic review: 14 clinical studies across facial hyperpigmentation, melasma, post-inflammatory and UV-induced hyperpigmentation.
All 14 reported statistically significant improvement, across facial hyperpigmentation, melasma, PIH and UV-induced pigmentation.
⚠️ The review’s own verdict is hedged: "the evidence for its use is limited. Further investigation is warranted."
7Open-LabelCited 35×n=83 · small study2020
In plain English: An international multi-centre approach combining a double-blind, controlled, split-face study of four-times versus twice-daily thiamidol with an open-label, real-world study of a full Thiamidol-containing face care regimen.
Roggenkamp D, et al. · Int J Cosmet Sci (2020)
The dosing study: split-face, four-times daily versus twice daily, which is where the "2 to 4 times daily" guidance comes from.
Split-face design controls for the individual, which is a genuine strength for a pigmentation endpoint.
⚠️ Two studies in one paper: the split-face randomized half (n = 34) and an OPEN-LABEL observational real-world half (n = 83, chromametry on 30), which carries no control for expectation.
8RCTCited 16×n=30 · small study2021
In plain English: After three weeks of application in 30 participants, ITR-treated skin showed NO significant lightening on its own, but a significantly lower lightness index than control after UVB-induced pigmentation.
Wanitphakdeedecha R, et al. · J Cosmet Dermatol (2021)
The distinction this study draws is the useful one: ITR did NOT lighten untreated skin, but it blunted the darkening UVB caused.
⚠️ "Both experimental sides showed no significant difference in terms of skin lightening after ITR application" — it is not a general skin lightener.
A pilot: 30 healthy participants, randomized but SINGLE-blinded.
9RCTCited 5×n=24 · very small study2024
In plain English: Two weeks of twice-daily ITR before Q-switched Nd:YAG laser lowered the INCIDENCE of post-inflammatory hyperpigmentation at week 4 (20.83% vs 50%, p = 0.028), while RMI, mean L* and hyperpigmentation score showed no significant difference between treatments at any visit.
Wanitphakdeedecha R, et al. · J Cosmet Dermatol (2024)
A prevention use: pre-treating before laser to reduce post-inflammatory hyperpigmentation.
PIH incidence at week 4 was 20.83% with twice-daily ITR against 50% with no application (p = 0.028).
⚠️ Every CONTINUOUS measure was null — relative melanin index, mean luminance and hyperpigmentation score showed no significant difference at any visit. Only the binary incidence moved.